RESEARCH ANIMAL SUPPORT FACILITY (RASF) The Research Animal Support Facility in Houston (RASF-H) and the RASF in Smithville (RASF-S) are centralized AAALAC International accredited core animal resources providing housing, procedure space, and research services to support MD Anderson's animal research studies. Dr. Peggy Tinkey, the previous RASF director, is retiring as of 1/2/2019. Dr. Vanessa Jensen has been appointed to serve as the director as of 9/1/2018, with Dr. Lezlee Coghlan serving as co-director. The 132,212 sq ft RASF-H facilities include barrier, hazard containment (biological/chemical/radioisotope) and quarantine areas for rodents, rabbits, fish, dogs, pigs, and primates. Specialized infrastructure and services include use of ?smart technology? to support operations (facility and building automation and computerized animal management systems), surgical suites, irradiators, and veterinary pathology laboratories. RASF faculty collaborate in the design and operation of specialized areas for behavioral, gnotobiotic, metabolism, and PDX rodent models. The 26,608 sq ft RASF-S is located at the 700-acre Science Park campus in central Texas and has 3 components: Animal Resource Services (ARS), Laboratory Animal Genetic Services (LAGS), and the Research Histology, Pathology, and Imaging Core (RHPI). The RASF's average daily cage census has increased 11% from grant Yr37. RASF-H served 264 cancer center members in 67 departments and all 16 CCSG programs, and RASF-S components supported 56 cancer center members in 23 departments and 16 CCSG programs. Most usage of RASF is from the Cancer Genetics and Epigenetics, Gastrointestinal Cancers, and Cancer Biology and Metastasis programs. During the current award period, the institution has provided approximately $15M in infrastructure and facility renovations, as well as $3,577,599 for the purchase of new equipment. In Yr42, peer-reviewed funding accounted for 96% of the total usage of the RASF. The annual operating budget of the RASF in Yr44 is expected to be $15,636,634, 6% ($875,532) of which is requested from the CCSG, with institutional support of $4,718,397 (30%) and philanthropic or other grant support of $589,831 (4%). The RASF has contributed to 881 manuscripts during the current award period, of which 632 (72%) were in journals with IF >5, and 255 (29%) in journals with IF >10.
The Specific Aims are:
Aim 1 : To provide high-quality, state-of-the-art, affordable animal facilities that enhance animal study reproducibility by controlling for and minimizing variables, including factors that affect the environment, animal health, model fidelity, and data integrity.
Aim 2 : To provide expert consultation and collaboration in areas including animal husbandry, veterinary care, surgical and imaging techniques, and rodent colony management.
Aim 3 : To provide specialized services such as rodent-specific genetic characterization and research histology for both live animals and cell lines, to develop new surgical techniques and imaging procedures, and to collaborate on the design of animal studies for therapeutic discovery and preclinical drug development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-43
Application #
9794657
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Korch, Christopher; Hall, Erin M; Dirks, Wilhelm G et al. (2018) Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. Int J Cancer 142:561-572
Lee, Jong-Ho; Liu, Rui; Li, Jing et al. (2018) EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell 70:197-210.e7
Brown, Justin C; Troxel, Andrea B; Ky, Bonnie et al. (2018) Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial. Clin Colorectal Cancer 17:32-40
Zhang, Hong; Wang, Yirong; Li, Jun et al. (2018) Biosynthetic energy cost for amino acids decreases in cancer evolution. Nat Commun 9:4124
Vilar-Compte, Diana; Shah, Dimpy P; Vanichanan, Jakapat et al. (2018) Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. J Med Virol 90:50-60
Bambhroliya, Arvind; Van Wyhe, Renae D; Kumar, Swaminathan et al. (2018) Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. PLoS One 13:e0192689
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Jain, N; Zhu, H; Khashab, T et al. (2018) Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia 32:663-674
Parker, Patricia A; Peterson, Susan K; Shen, Yu et al. (2018) Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. J Clin Oncol 36:2630-2638
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133

Showing the most recent 10 out of 12418 publications